Recent Finacing
Recent Raise
ProJenX is a New York City–based clinical-stage biotechnology company developing prosetin, an oral, brain-penetrant MAP4K inhibitor for ALS, using a patient-specific, cell-based drug discovery platform from Project ALS/Columbia.
